Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy (Q59356669)

8

object named as

Anna Kanerva

0 references

author name string

João Manuel Santos

1

0 references

Víctor Cervera-Carrascon

2

0 references

Riikka Havunen

3

0 references

Sadia Zafar

4

0 references

Mikko Siurala

5

0 references

Suvi Sorsa

6

0 references

Marjukka Anttila

Trial Watch: Adoptive cell transfer for oncological indications

7

0 references

language of work or name

English

0 references

publication date

5 September 2018

0 references

published in

Molecular Therapy

0 references

volume

26

0 references

issue

9

0 references

page(s)

2243-2254

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adoptive cell transfer as personalized immunotherapy for human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Emerging Opportunities and Challenges in Cancer Immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Elements of cancer immunity and the cancer-immune set point

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Oncolytic viruses: a new class of immunotherapy drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Cytokines in cancer pathogenesis and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Plasticity of human CD4 T cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

CD86 has sustained costimulatory effects on CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Cardiac toxicity of high-dose chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Vascular Complications of Cancer Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Arterial stiffness is related to systemic inflammation in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Locally produced tumor necrosis factor-alpha mediates interleukin-2-induced lung injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.06.001

Specificity of adoptive chemoimmunotherapy of established syngeneic tumors

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30017877

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30017877